NASH

Company spotlight_Biostart Magazine

Promethera Biosciences

November 8, 2019 Jane 0

Many biotech companies are formed out of early research conducted in universities. This is the reason for the increasing number of technology transfer offices.  

Promethera Biosciences which focuses on liver disease, is one such company. Founded in 2009, it was the brainchild of Professor Etienne Sokal, pediatric hepatologist at Cliniques Universitaires St Luc and the Université Catholique de Louvain Technology Transfer Office.

It drew on the longstanding, pioneering work in paediatric liver transplantation at Cliniques St Luc, the first European hepatocyte transplantation program and the discovery in 2005 by Professor Sokal and Mustapha Najimi of a unique liver-derived mesenchymal stem cell, obtained from…

Attached Issue № 0819
Company spotlight_Biostart Magazine

The CEO perspective

October 2, 2019 Jane 0

Algernon Pharmaceuticals Inc. is a publicly-traded clinical-stage drug development company, focused on non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). Their discovery program is based on drug repurposing; finding new uses for already approved drugs.

Christopher J. Moreau joined Algernon (previously called Breathtec Biomedical) as CEO in March 2018 to bring new leadership to the company. His first mandate was to review the company’s key technology and to make recommendations to the board on the company’s business plan.

Behind the scenes at Algernon

In the fall of 2018, Algernon acquired a company called Nash Pharmaceuticals. Nash’s business model was to…

Attached Issue № 0819